Lymphocyte suppression by rolipram with other immunosuppressive drugs
Journal of Clinical Pharmacology, ISSN: 0091-2700, Vol: 39, Issue: 8, Page: 794-799
1999
- 6Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- CrossRef5
- Captures2
- Readers2
Article Description
Pentoxifylline, a nonselective phosphodiesterase inhibitor, has immunomodulatory activity in vitro and in vivo and potentiates the suppressive effects of glucocorticoids and cyclosporine on lymphocyte proliferation in vitro. Since phasphodiesterase isotypes 3 and 4 predominate in lymphocytes, the authors measured the suppressive effect of rolipram alone and in combination with low concentrations of methylprednisolone and calcineurin enzyme inhibitors, compared to that of pentoxlfylline on mitogen-stimulated lymphocyte proliferation. The percent inhibition ofH-thymidine incorporation by both 10 and 10 mol/L concentrations of rolipram were significantly greater than that by both 10 mol/L pentoxifylline and 10 mol/L methylprednisolone. The percent inhibition by the combination of 10, but not 10, mol/L rolipram and methylprednisolone was significantly greater than that by 10 mol/L pentoxifylline and methylprednisolone. Potentiation of the suppressive effects of cyclasporine and tacrolimus by roliprom was less consistent. Measurement of cell culture supernatant concentrations of interferon gamma and interleukin-10 indicate that one of the mechanisms underlying the immunosuppressive activity of rolipram is a significantly disproportionate inhibition of the proinflammatory cytokine, interferon gamma. (C)1999 the American College of Clinical Pharmacology.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033334317&origin=inward; http://dx.doi.org/10.1177/00912709922008443; http://www.ncbi.nlm.nih.gov/pubmed/10434230; https://accp1.onlinelibrary.wiley.com/doi/10.1177/00912709922008443; https://dx.doi.org/10.1177/00912709922008443; https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922008443
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know